Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
HTH-01-091
Cat. No.:
OB0225LY-0182
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
HTH-01-091 is a novel small molecule compound with the potential to modulate neuronal activity.
Synonym:
HTH-01091; HTH01-091; HTH 01-091; HTH 01091; 2000209-42-5; 9-(3,5-Dichloro-4-hydroxyphenyl)-1-{trans-4-[(dimethylamino)methyl]cyclohexyl}-3,4-dihydropyrimido[5,4-c]quinolin-2(1H)-one; 9-(3,5-Dichloro-4-hydroxyphenyl)-1-(rel-(1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-3,4-dihydropyrimido[5,4-c]quinolin-2(1H)-one
CAS No.:
2000209-42-5
Compound CID:
131801426
Formula:
C26H28Cl2N4O2
Formula Weight:
499.43
Specification
Relative Density:
1.327 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
HTH-01-091 can be used in neuroscience research or play an important role in modeling neurodegenerative diseases.
Library Information
Targets:
Serine/Threonine kinases; Kinase families
Receptors:
MELK; RIPK2; MLCK; CLK2; Pim; PIM1/2/3; DYRK3; smMLCK; CDK
Pathways:
JAK/STAT signaling; PI3K/Akt/mTOR signaling; Cell cycle/Checkpoint; Apoptosis; Metabolism; Chromatin/Epigenetic; Tyrosine kinase/adaptors; NF-κB
Plate Number:
AOCL-3
Plate Location:
c5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
5 mg/mL; 10 mM
